| Date | Company | Compound | Disease | Type of agreement | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2011-04-21 | Iris Pharma (France) OPIA Technologies (France) | Eyeprim® device | Licensing |
Ophtalmology | Licensing agreement | |
| 2011-04-19 | Lonza (Switzerland) ORGANOBALANCE (Germany) | products containing a probiotic Lactobacillus strain | Licensing |
Nutrition | Licensing agreement | |
| 2011-04-19 | Medigene (Germany) Triton Pharma (Canada) | Veregen® ointment (made from the extract of green tea leaves - catechins) | External genital warts | licensing |
Gynecology - Infectious diseases | Licensing agreement |
| 2011-04-19 | Genmab (Denmark) Seattle Genetics (USA - WA) | antibody-drug conjugate (ADC) | R&D |
Cancer - Oncology | R&D agreement | |
| 2011-04-18 | UCB (Belgium) Katholieke Universiteit Leuven (Belgium) | R&D |
Immunology - Immunological diseases - Autoimmune diseases | R&D agreement | ||
| 2011-04-18 | Inovio Pharmaceuticals (USA) Transgene (France) ChronTech Pharma (Sweden) | novel therapeutic vaccination strategy against genotype 1 hepatitis C virus (HCV) | hepatitis C | R&D collaboration |
Infectious diseases | R&D agreement |
| 2011-04-14 | 4SC (Germany) Yakult Honsha (Japan) | resminostat | hepatocellular carcinoma - colorectal cancer | Licensing |
Cancer - Oncology | Licensing agreement |
| 2011-04-13 | Antitope (UK) Cellmid (Australia) | humanised anti-midkine antibody | R&D collaboration |
Autoimmune diseases - Immunological diseases - Inflammatory diseases | ||
| 2011-04-12 | Vivalis (France) undisclosed worldwide vaccine company | EB66® cell line for the production of a human vaccine candidate | undisclosed | R&D |
||
| 2011-04-12 | Vernalis (UK) Biogen Idec (USA) | A2A receptor antagonist programme | Parkinson's disease and other neurological disorders | licensing |
Neurodegenerative diseases - CNS diseases | Licensing agreement |
| 2011-04-12 | Xention (UK) Ono Pharmaceutical (Japan) | small molecules against ion channels | undisclosed | R&D |
undisclosed | R&D agreement |
| 2011-04-11 | MorphoSys (Germany) ContraFect (USA) | therapeutic antibodies | R&D development licensing commercialisation |
Infectious diseases | R&D agreement | |
| 2011-04-11 | Lonza (Switzerland) Roche (Switzerland) | MycoTOOL® mycoplasma Polymerase Chain Reaction (PCR) assays | distribution |
Distribution agreement | ||
| 2011-04-11 | Bavarian Nordic (Denmark) US Government (USA) | Imvamune® smallpox vaccine | smallpox | development | Infectious diseases | Development agreement |
| 2011-04-08 | ReNeuron (UK) NHS Blood and Transplant (UK) | CTXcryo® stem cell product | peripheral arterial disease | manufacturing |
Cardiovascular diseases | Production agreement |
| 2011-04-07 | OctoPlus (The Netherlands) one of top 10 biopharmaceutical company | undisclosed peptide | undisclosed | development |
undisclosed | Development agreement |
| 2011-04-07 | Novartis (Switzerland) Meda (Sweden) | Elidel® (pimecrolimus) | atopic dermatitis | global rights |
Dermatological diseases | Product acquisition |
| 2011-04-06 | Oxford BioTherapeutics (UK) BioWa (Japan) | POTELLIGENT® Technology platform | licensing |
Cancer - Oncology | Licensing agreement | |
| 2011-04-05 | Integromics (Spain) Ingenuity Systems (USA) | IT Omics tools | collaboration licensing |
Collaboration agreement | ||
| 2011-04-05 | Critical Pharmaceuticals (UK) Polytherics (UK) | novel injectable sustained release drug delivery system for an undisclosed high value biological drug | R&D |
R&D agreement |
